Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (10190)	8/11/2009 1:17:16 AM
From: Harold Engstrom	1 Recommendation Respond to of 10345

That comparison between US sales of Copaxone and Tysabri is amazing. IMO, it speaks volumes about how poorly therapy choices are made here. The clinical trial data for Copaxone is so weak that I think the Last Measured approach, if used, might have accounted for any measured effect. In another 2 years, I hope Tysabri has enough time under its belt that all patients with active MS can use Tysabri with confidence. If patients do not have active MS then data suggests (to me) that copaxone is not justified.